Valbiotis SAS (ALVAL) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.592x

Based on the latest financial reports, Valbiotis SAS (ALVAL) has a cash flow conversion efficiency ratio of -0.592x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.12 Million ≈ $-4.82 Million USD) by net assets (€6.96 Million ≈ $8.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Valbiotis SAS fund operations to measure how many days the company can operate on defensive assets alone.

Valbiotis SAS - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Valbiotis SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Valbiotis SAS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Valbiotis SAS ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Higher Way Electronic Co Ltd
TWO:3268
-0.040x
ECO WAVE POW.GL. SP.ADR/8
F:1KW0
N/A
WITTED MEGACORP OYJ EO 1
F:8OS
0.106x
Eutilex.Co.Ltd
KQ:263050
-0.083x
Mmcité a.s.
PR:MMCTE
N/A
KPS Consortium Bhd
KLSE:9121
0.004x
Flagship Investments Ltd
AU:FSI
-0.006x
Marti Otel Isletmeleri AS
IS:MARTI
-0.004x

Annual Cash Flow Conversion Efficiency for Valbiotis SAS (2015–2025)

The table below shows the annual cash flow conversion efficiency of Valbiotis SAS from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Valbiotis SAS (ALVAL) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €6.96 Million
≈ $8.14 Million
€-8.04 Million
≈ $-9.40 Million
-1.155x -3.77%
2024-12-31 €10.37 Million
≈ $12.12 Million
€-11.54 Million
≈ $-13.49 Million
-1.113x -170.73%
2023-12-31 €19.60 Million
≈ $22.91 Million
€-8.06 Million
≈ $-9.42 Million
-0.411x +40.47%
2022-12-31 €13.31 Million
≈ $15.56 Million
€-9.19 Million
≈ $-10.75 Million
-0.690x -37.31%
2021-12-31 €14.23 Million
≈ $16.64 Million
€-7.16 Million
≈ $-8.37 Million
-0.503x -232.07%
2020-12-31 €7.07 Million
≈ $8.27 Million
€2.69 Million
≈ $3.15 Million
0.381x +163.19%
2019-12-31 €8.21 Million
≈ $9.60 Million
€-4.95 Million
≈ $-5.78 Million
-0.603x +1.80%
2018-12-31 €7.41 Million
≈ $8.66 Million
€-4.55 Million
≈ $-5.31 Million
-0.614x -186.99%
2017-12-31 €10.16 Million
≈ $11.88 Million
€-2.17 Million
≈ $-2.54 Million
-0.214x +90.81%
2016-12-31 €369.00K
≈ $431.40K
€-858.00K
≈ $-1.00 Million
-2.325x +73.80%
2015-12-31 €80.00K
≈ $93.53K
€-710.00K
≈ $-830.06K
-8.875x --

About Valbiotis SAS

PA:ALVAL France Packaged Foods
Market Cap
$23.90 Million
€20.44 Million EUR
Market Cap Rank
#24529 Global
#400 in France
Share Price
€0.86
Change (1 day)
-2.70%
52-Week Range
€0.55 - €1.21
All Time High
€10.54
About

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; T… Read more